Gast ::
| Hauptseite > Publikationsdatenbank > Toward a Universal Readout for 18 F-Labeled Amyloid Tracers: The CAPTAINs Study > print |
| Hauptseite > Publikationsdatenbank > Toward a Universal Readout for 18 F-Labeled Amyloid Tracers: The CAPTAINs Study > print |
| 001 | 905078 | ||
| 005 | 20230123101926.0 | ||
| 024 | 7 | _ | |a 10.2967/jnumed.120.250290 |2 doi |
| 024 | 7 | _ | |a 0022-3123 |2 ISSN |
| 024 | 7 | _ | |a 0097-9058 |2 ISSN |
| 024 | 7 | _ | |a 0161-5505 |2 ISSN |
| 024 | 7 | _ | |a 1535-5667 |2 ISSN |
| 024 | 7 | _ | |a 2159-662X |2 ISSN |
| 024 | 7 | _ | |a 2128/32294 |2 Handle |
| 024 | 7 | _ | |a 33712532 |2 pmid |
| 024 | 7 | _ | |a WOS:000770317400004 |2 WOS |
| 037 | _ | _ | |a FZJ-2022-00377 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Bischof, Gerard Nisal |0 P:(DE-Juel1)166265 |b 0 |e Corresponding author |
| 245 | _ | _ | |a Toward a Universal Readout for 18 F-Labeled Amyloid Tracers: The CAPTAINs Study |
| 260 | _ | _ | |a New York, NY |c 2021 |b Soc. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1667394647_29954 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a To date, 3 18F-labeled PET tracers have been approved for assessing cerebral amyloid plaque pathology in the diagnostic workup of suspected Alzheimer disease (AD). Although scanning protocols are relatively similar across tracers, U.S. Food and Drug Administration- and the European Medicines Agency-approved visual rating protocols differ among the 3 tracers. This proof-of-concept study assessed the comparability of the 3 approved visual rating protocols to classify a scan as amyloid-positive or -negative, when applied by groups of experts and nonexperts to all 3 amyloid tracers. Methods: In an international multicenter approach, both expert (n = 4) and nonexpert raters (n = 3) rated scans acquired with 18F-florbetaben, 18F-florbetapir and 18F-flutemetamol. Scans obtained with each tracer were presented for reading according to all 3 approved visual rating protocols. In a randomized order, every single scan was rated by each reader according to all 3 protocols. Raters were blinded for the amyloid tracer used and asked to rate each scan as positive or negative, giving a confidence judgment after each response. Percentage of visual reader agreement, interrater reliability, and agreement of each visual read with binary quantitative measures (fixed SUV ratio threshold for positive or negative scans) were computed. These metrics were analyzed separately for expert and nonexpert groups. Results: No significant differences in using the different approved visual rating protocols were observed across the different metrics of agreement in the group of experts. Nominal differences suggested that the 18F-florbetaben visual rating protocol achieved the highest interrater reliability and accuracy especially under low confidence conditions. For the group of nonexpert raters, significant differences between the different visual rating protocols were observed with overall moderate-to-fair accuracy and with the highest reliability for the 18F-florbetapir visual rating protocol. Conclusion: We observed high interrater agreement despite applying different visual rating protocols for all 18F-labeled amyloid tracers. This implies that the results of the visual interpretation of amyloid imaging can be well standardized and do not depend on the rating protocol in experts. Consequently, the creation of a universal visual assessment protocol for all amyloid imaging tracers appears feasible, which could benefit especially the less-experienced readers.Keywords: amyloid PET; florbetaben; florbetapir; flutemetamol; visual rating standardization. |
| 536 | _ | _ | |a 5253 - Neuroimaging (POF4-525) |0 G:(DE-HGF)POF4-5253 |c POF4-525 |f POF IV |x 0 |
| 536 | _ | _ | |a 5254 - Neuroscientific Data Analytics and AI (POF4-525) |0 G:(DE-HGF)POF4-5254 |c POF4-525 |f POF IV |x 1 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Bartenstein, Peter |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Barthel, Henryk |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a van Berckel, Bart |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Doré, Vincent |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a van Eimeren, Thilo |0 P:(DE-Juel1)169110 |b 5 |
| 700 | 1 | _ | |a Foster, Norman |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Hammes, Jochen |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Lammertsma, Adriaan A. |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Minoshima, Satoshi |0 P:(DE-HGF)0 |b 9 |
| 700 | 1 | _ | |a Rowe, Chris |0 P:(DE-HGF)0 |b 10 |
| 700 | 1 | _ | |a Sabri, Osama |0 P:(DE-HGF)0 |b 11 |
| 700 | 1 | _ | |a Seibyl, John |0 P:(DE-HGF)0 |b 12 |
| 700 | 1 | _ | |a Van Laere, Koen |0 P:(DE-HGF)0 |b 13 |
| 700 | 1 | _ | |a Vandenberghe, Rik |0 P:(DE-HGF)0 |b 14 |
| 700 | 1 | _ | |a Villemagne, Victor |0 P:(DE-HGF)0 |b 15 |
| 700 | 1 | _ | |a Yakushev, Igor |0 P:(DE-HGF)0 |b 16 |
| 700 | 1 | _ | |a Drzezga, Alexander |0 P:(DE-Juel1)177611 |b 17 |
| 773 | _ | _ | |a 10.2967/jnumed.120.250290 |g Vol. 62, no. 7, p. 999 - 1005 |0 PERI:(DE-600)2040222-3 |n 7 |p 999 - 1005 |t Journal of nuclear medicine |v 62 |y 2021 |x 0022-3123 |
| 856 | 4 | _ | |y Restricted |z StatID:(DE-HGF)0599 |u https://juser.fz-juelich.de/record/905078/files/Toward%20a%20Universal%20Readout_fulltext.pdf |
| 856 | 4 | _ | |y OpenAccess |z StatID:(DE-HGF)0510 |u https://juser.fz-juelich.de/record/905078/files/Towards%20a%20Universal%20Readout_Bischof_PostPrint.pdf |
| 909 | C | O | |o oai:juser.fz-juelich.de:905078 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a University Hospital Cologne, Multimodal Neuroimaging Group, Department of Nuclear Medicine, Cologne, Germany; gerard.bischof@uk-koeln.de. |0 I:(DE-HGF)0 |b 0 |6 P:(DE-Juel1)166265 |
| 910 | 1 | _ | |a Department of Nuclear Medicine, LMU Munich, Munich, Germany |0 I:(DE-HGF)0 |b 1 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a University Hospital of Leipzig, Department of Nuclear Medicine, Leipzig, Germany |0 I:(DE-HGF)0 |b 2 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Amsterdam University Medical Centers, Location VUmc Radiology and Nuclear Medicine, Amsterdam, The Netherlands |0 I:(DE-HGF)0 |b 3 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a CSIRO Health and Biosecurity, Parkville 3052, Victoria, Australia |0 I:(DE-HGF)0 |b 4 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Australia |0 I:(DE-HGF)0 |b 4 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a University Hospital Cologne, Multimodal Neuroimaging Group, Department of Nuclear Medicine, Cologne, Germany |0 I:(DE-HGF)0 |b 5 |6 P:(DE-Juel1)169110 |
| 910 | 1 | _ | |a Department of Neurology, University Hospital Cologne, Cologne, Germany |0 I:(DE-HGF)0 |b 5 |6 P:(DE-Juel1)169110 |
| 910 | 1 | _ | |a German Center of Neurodegenerative Disease (DZNE), Bonn, Germany |0 I:(DE-HGF)0 |b 5 |6 P:(DE-Juel1)169110 |
| 910 | 1 | _ | |a Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, Utah |0 I:(DE-HGF)0 |b 6 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a University Hospital Cologne, Multimodal Neuroimaging Group, Department of Nuclear Medicine, Cologne, Germany |0 I:(DE-HGF)0 |b 7 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Amsterdam University Medical Centers, Location VUmc Radiology and Nuclear Medicine, Amsterdam, The Netherlands |0 I:(DE-HGF)0 |b 8 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, Utah |0 I:(DE-HGF)0 |b 9 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a CSIRO Health and Biosecurity, Parkville 3052, Victoria, Australia |0 I:(DE-HGF)0 |b 10 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Australia |0 I:(DE-HGF)0 |b 10 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a University Hospital of Leipzig, Department of Nuclear Medicine, Leipzig, Germany |0 I:(DE-HGF)0 |b 11 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Institute for Neurodegenerative Disorders, New Haven, Connecticut |0 I:(DE-HGF)0 |b 12 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Nuclear Medicine and Molecular Imaging, University Hospital Leuven and Department of Imaging and Pathology KU Leuven, Leuven, Belgium |0 I:(DE-HGF)0 |b 13 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Memory Clinic, University Hospital Leuven and Department of Neurosciences, KU Leuven, Belgium |0 I:(DE-HGF)0 |b 14 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a CSIRO Health and Biosecurity, Parkville 3052, Victoria, Australia |0 I:(DE-HGF)0 |b 15 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Australia |0 I:(DE-HGF)0 |b 15 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Department of Nuclear Medicine, Technical University of Munich, Germany; and |0 I:(DE-HGF)0 |b 16 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 17 |6 P:(DE-Juel1)177611 |
| 910 | 1 | _ | |a University Hospital Cologne, Multimodal Neuroimaging Group, Department of Nuclear Medicine, Cologne, Germany |0 I:(DE-HGF)0 |b 17 |6 P:(DE-Juel1)177611 |
| 910 | 1 | _ | |a German Center of Neurodegenerative Disease (DZNE), Bonn, Germany |0 I:(DE-HGF)0 |b 17 |6 P:(DE-Juel1)177611 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5253 |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5254 |x 1 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-27 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-27 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b J NUCL MED : 2019 |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-01-27 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J NUCL MED : 2019 |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-01-27 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-2-20090406 |k INM-2 |l Molekulare Organisation des Gehirns |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-2-20090406 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|